In a statement, Wegovy's maker Novo Nordisk said it was "encouraged" by the new guidance from CMS but said it hopes to see Part D coverage expanded for "obesity medicines when used for chronic weight management." The drug maker is among those pushing for Congress to expand coverage of treatments for obesity
Athletes looking to improve their body composition, enhance recovery, and support joint health may find AOD 9604 particularly beneficial
23, Novo Nordisk released late-stage study results showing participants who took its next-generation obesity drug, CagriSema, didn't lose as much weight as those who took rival Eli Lilly's Zepbound
In the 3-NP model of HD, the combination therapy significantly blocked 3-NP-induced striatal lesion volume by 83%, and reduced 3-NP induced lipid oxidation and DNA oxidation
If the vial can hold 5 mL, that water volume halves the concentration from 32 mg/mL to 16 mg/mL and may reduce the copper-peptide sting